Michael Bromley is a Professor in Medical Mycology at the University of Manchester and is the Director of the Manchester Fungal Infection Group. His research focuses on drug discovery and drug resistance in fungal pathogens. While working at F2G Ltd and throughout his academic research career he has been involved in the evaluation of the antifungal drug Olorofim. He has led a collaborative project to generate a genome-scale knockout mutant library in the filamentous fungal pathogen Aspergillus fumigatus and has developed and employed functional genomics technologies to understand genetic and environmental drivers of pathogenicity and drug resistance in fungi.